Characterisation Of Cumulus Cell Molecular Mediators Of Oocyte Health
Funder
National Health and Medical Research Council
Funding Amount
$451,896.00
Summary
Many women are poorly fertile because of poor egg quality due to age, disease and lifestyle. IVF can assist, but requires large doses of hormone, which can lead to significant health risks. IVM is an alternative lab technique to IVF, but has very poor success. We discovered that synthetic proteins copied from recently discovered egg proteins can be added to the egg and substantially increase IVM success. Answering why will further will aid treatment for infertile women
Re-energising The Preimplantation Embryo To Extend Lifetime Health
Funder
National Health and Medical Research Council
Funding Amount
$1,156,936.00
Summary
Diseases of aging are associated with shortening at the ends of chromosomes called telomeres. The length of an individual’s telomeres is established during embryo development, and in situations where embryo development is compromised such as with maternal obesity the normal process of telomere lengthening may not occur. We will determine how such disruptions in embryo telomere lengthening contribute to poor health in adulthood and test ways to restore the natural process.
Advancing maternal age is associated with the progressive loss of fertility, increased miscarriage and a greater risk of bearing children with birth defects. These adverse reproductive outcomes result, in part, from the loss of egg quality with age. We aim to identify and characterise genes involved in the age-related decline in egg quality. The long-term goal of this research is to develop novel strategies to improve fertility outcomes for women who chose to delay pregnancy until later in life.
Optimising Female Fertility: Controlling Ovulation And Promoting Embryo Developmental Potential
Funder
National Health and Medical Research Council
Funding Amount
$459,270.00
Summary
A good quality egg at the right time is required to make a healthy embryo, influencing its lifetime health trajectory. My research aims to determine how the female ovary produces a good quality egg and releases it at the right time. This is essential for improving reproductive health in women and will identify how maternal health influences egg quality and the earliest stages of embryo growth, providing the healthiest start to life.
Female Reproductive Health Preservation By Nicotinamide Adenine Dinucleotide (NAD+) And Sirtuin2 (SIRT2)
Funder
National Health and Medical Research Council
Funding Amount
$410,983.00
Summary
Cancer treatment can be severely toxic to women’s eggs. Increasing numbers of women who survive cancer therefore become infertile and prematurely deprived of hormonal support whilst still in their reproductive years. This project will use state-of-the-art techniques to interrogate newly uncovered pathways that can protect eggs from treatment-induced injury thereby greatly improving the quality of life for female cancer survivors.
The Role Of Primordial Follicle Activation In Premature Ovarian Failure
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
As women age, both the quality and quantity of their eggs decline and their chances of conceiving plummets. Premature ovarian failure (POF) is a disease of infertility, diagnosed in 3% of all women, defined by the early onset of menopause before age 40. Our poor understanding of the factors that regulate female egg supply remains a major limitation in treating POF. I will study key factors responsible for controlling egg number, with practical implications for POF diagnosis and treatment.
The Effect Of Oxygen Tension On Primary And Primordial Follicle Activation In The Primate Ovary
Funder
National Health and Medical Research Council
Funding Amount
$403,956.00
Summary
Oncofertility, bridges oncology and reproductive medicine in order to apply new fertility preservation options for young patients with fertility-threatening diseases or treatments. Development of the three dimensional (3-D) tissue culture system for follicle maturation is a novel method of replicating the native environment of the growing egg. The ultimate goal of the project is to develop and optimise an in vitro culture procedure that can be translated to support human follicle development.
Molecular Basis For Female Age-associated Decline In Oocyte Quality And Fertility
Funder
National Health and Medical Research Council
Funding Amount
$71,792.00
Summary
Many women cannot have children because of suboptimal egg quality, often due to ageing. In order for novel strategies to be developed for improving egg quality, it will first be important to understand how key factors in eggs are regulated. This project will use state-of-the-art techniques to interrogate a pivotal pathway we have discovered in eggs that could be responsible for age-related decline and could hold the key to new approaches for rejuvenating eggs.
Exploitation Of Unique Growth Factors To Develop New Products For Infertility Treatment
Funder
National Health and Medical Research Council
Funding Amount
$132,525.00
Summary
Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro ma ....Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro maturation (IVM), which drastically reduces the use-cost of drugs and the stress to patients. However, oocyte IVM has been slow to live up to its potential and the technology is still not in widespread clinical practice, mainly due to disappointing success rates in women. We have been studying oocyte IVM in animals for many years, and have recently made a significant technological breakthrough, improving success rates by ~50%. In this field, a 50% increase in efficiency is substantial and has significant clinical and commercial application. Currently, we are the only group worldwide with this technology. Over the course of this 2-year project we will conduct follow-up experiments to refine this discovery and investigate the feasibility of using this approach to treat human infertility. We are already in negotiations with two medical device manufacturers to licence this technology. We expect that this project will lead to a series of products and technologies that will enter a clinical trial for the treatment of infertility within 2-3 years.Read moreRead less